Paul P. Bergmans
Breda, NB, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Evaluation of an interdisciplinary electronic consultation service between general practitioners and medical specialists in The Netherlands: a prospective cohort study.
Journal: Family practice
Published: March 05, 2026
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study.
Journal: Arthritis research & therapy
Published: January 18, 2023
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Journal: Arthritis research & therapy
Published: November 22, 2022
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.
Journal: Rheumatology (Oxford, England)
Published: October 05, 2022
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.
Journal: Annals of the rheumatic diseases
Published: June 01, 2022
Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort.
Journal: Clinical and experimental rheumatology
Published: March 09, 2022
Safety of ustekinumab in adolescent patients with moderate-to-severe plaque psoriasis: real-world evidence from an ongoing European study (NCT03218488).
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 30, 2021
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.
Journal: Annals of the rheumatic diseases
Published: October 08, 2021
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
Journal: Annals of the rheumatic diseases
Published: June 16, 2021
Effect of a price display intervention on laboratory test ordering behavior of general practitioners.
Journal: BMC family practice
Published: May 06, 2021
Last Updated: 09/26/2026